Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?
Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why Hologic’s Breast Cancer Index data matter for precision oncology beyond recurrence risk
Hologic’s Breast Cancer Index is changing endocrine therapy decisions. The bigger test is adoption in real-world breast cancer care.
Medical Devices & Diagnostics
How Agendia’s breast cancer assays are testing the limits of race-based clinical assumptions
Race matters in care access, but tumor biology may drive response. Agendia’s FLEX data sharpen the breast cancer equity debate.
Features & Analysis
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in
Pharma & Biotech
Can Guardant Health and Trial Library fix the clinical trial inclusion gap with AI and genomics?
Guardant Health and Trial Library team up to improve cancer trial access using AI and genomic data. Discover how this could reshape enrollment and equity in oncology.